MedTrace Logo

Fluorescent Sentinel Lymph Node Identification in Colon Carcinoma Using Intravenous Bevacizumab-800CW

NCT05497726 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-11-07

No results posted yet for this study

Summary

This prospective study aims to assess the safety and feasibility of lymph node identification using bevacizumab-800CW in patients with cT1-3N0-2 tumours, using intravenous administration.

Conditions

  • Colorectal Neoplasms
  • Colon Neoplasm
  • Sentinel Lymph Node
  • Fluorescence

Interventions

PROCEDURE

Sentinel lymph node detection using intravenous bevacizumab-800CW

Sentinel lymph node detection using intravenous bevacizumab-800CW

Sponsors & Collaborators

  • Meander Medical Center

    lead OTHER

Principal Investigators

  • Esther Consten, prof. dr. · Meander Medisch Centrum

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-27
Primary Completion
2023-07-10
Completion
2023-10-10

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05497726 on ClinicalTrials.gov